Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.10.026 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Rayan Kaedbey und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: rayan.kaedbey@mcgill.ca. Hauptthemen laut MEDLINE: Multiple Myeloma, Salvage Therapy, Hematopoietic Stem Cell Transplantation, Neoplasm Recurrence, Local. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Salvage autologous stem cell transplantation (ASCT2) remains a treatment option for selected patients with relapsed multiple myeloma (MM). In this multicenter study, we conducted a retrospective analysis using the Canadian Myeloma Research Group (CMRG) database to evaluate real-world outcomes of ASCT2 in the maintenance era. PATIENTS AND METHODS: Three hundred and fifty-two patients underwent ASCT2 following progression after ASCT1 between 2012 and 2021. Progression-free survival (PFS), overall survival (OS), depth of response, and the impact of maintenance therapy after ASCT2 were assessed, with further stratification based on maintenance use after ASCT1. RESULTS: Our analysis demonstrated that post-ASCT2 maintenance therapy was associated with improved outcomes, particularly in patients who had also received maintenance after ASCT1 (25.2 months (95% CI, 20.8-39.6) versus 11.6 months (95% CI, 8.51-18.8)). In patients receiving lenalidomide maintenance after ASCT1, a remission lasting less than 3 years represented a high risk group with poor outcomes with an ASCT2. CONCLUSION: While novel agents continue to expand treatment options, ASCT2 remains a viable therapeutic strategy in appropriately selected patients, especially those with durable responses to prior therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada. Electronic address: rayan.kaedbey@mcgill.ca.
- Department of Medicine, BC Cancer, Vancouver Centre, Vancouver, Canada.
- Department of Medical Oncology and Hematology, Canadian Myeloma Research Group, Princess Margaret Cancer Centre, Toronto, Canada.
- Department of Medicine, Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
- Canadian Myeloma Research Group, Vaughan, Ontario, Canada.
- Department of Medicine, The Ottawa Hospital, Ottawa, Ontario, Canada.
Zitieren
APA
Kaedbey, R., Venner, C. P., Reece, D., Hay, K., Gul, E., Su, J., McCurdy, A., Chu, M. P., Jimenez-Zepeda, V. H., Song, K., Mian, H., Louzada, M., Sebag, M., Reiman, A., White, D., Stakiw, J., Kotb, R., Aslam, M., Masih-Khan, E., …, & LeBlanc, R. (2025). Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.10.026
Vancouver
Kaedbey R, Venner CP, Reece D, Hay K, Gul E, Su J, et al. Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.10.026
BibTeX
@article{Kaedbey2025,
author = {Kaedbey, Rayan and Venner, Christopher P and Reece, Donna and Hay, Kevin and Gul, Engin and Su, Jiandong and McCurdy, Arleigh and Chu, Michael P and Jimenez-Zepeda, Victor H and Song, Kevin and Mian, Hira and Louzada, Martha and Sebag, Michael and Reiman, Anthony and White, Darrell and Stakiw, Julie and Kotb, Rami and Aslam, Muhammad and Masih-Khan, Esther and Bergstrom, Debra and LeBlanc, Richard},
title = {Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.10.026}
}
EUVIMED